abstract: PURPOSE: We present our experience with percutaneous rheolytic treatment with the AngioJet thrombectomy catheter for @entity810 . CASE REPORT: A 63-year-old male @entity1 with @entity715 presented 48 hours after the onset of acute nonradiating @entity812 . @entity715 was documented by CT angiography, 99mTc- @entity12306 , and digital subtraction angiography. A percutaneous thrombectomy was performed with the AngioJet catheter. At the end of the procedure, the arterial lumen was patent, and no underlying @entity850 or other deformity of the arterial wall was found. Thus, the cause of the obstruction was considered to be an embolus. After the procedure, urokinase was given to prevent distal occlusions from emboli that could have escaped mechanical thrombectomy. Heparin was also administered. The @entity1 was released from the hospital with a patent renal unit and ameliorated serum @entity1011 concentration. CONCLUSION: We propose the use of the AngioJet thrombectomy catheter for the percutaneous treatment of @entity810 .

title: Percutaneous rheolytic thrombectomy for treatment of XXXX .

entities_list: @entity812 :: ('MESH:D021501', 'Disease') :: ['flank pain']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['acute renal-artery thrombosis']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['renal-artery thrombosis', 'Thrombosis']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

answer: @entity810 :: (MESH:D058186,Disease) :: ['acute renal-artery thrombosis']


abstract: Thirty cases of @entity157 ( @entity157 ) were investigated immunocytochemically for expression of @entity2393 molecule and of collagen IV. Immunoreactivity was related to the @entity5 proliferation index, as detected by @entity1364 immunostaining, and to @entity5 size and grade. Membrane @entity2393 immunoreactivity was detected in the neoplastic cells of all cases, though two different staining patterns were clearly recognized. In 14 cases, @entity2393 immunoreactivity was confined to the cell-stroma interface, showing the same polarized pattern as the non-neoplastic cell counterpart. This staining pattern was associated significantly (P < 0.0001) with low @entity1364 labelling (i.e. less than 20 per cent of neoplastic cells showing nuclear immunostaining. Conversely, 16 cases showed non-polarized pericellular @entity2393 immunostaining. This staining pattern was significantly associated (P < 0.0001) with high @entity1364 labelling (more than 20 per cent of immunoreactive cells) and with @entity5 size greater than 4 cm in diameter (P < 0.0001). @entity2393 , collagen IV, and @entity1364 immunoreactivities, however, did not correlate with the histological grade. The data emphasize that neoplastic progression of @entity5462 may be correlated with an aberrant expression of adhesion molecules and with a disruption of the collagen IV complement of basal membranes.

title: Patterns of integrin common chain beta 1 and collagen IV immunoreactivity in XXXX . Correlations with @entity5 growth rate, grade and size.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity2393 :: ('3688', 'Gene') :: ['beta 1 integrin', 'beta 1 Integrin']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

answer: @entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']


abstract: BACKGROUND: Surgical options for @entity15 ( @entity15 ) related to @entity4254 ( @entity4254 ), a severe and disabling @entity2531 , include percutaneous rhizotomy, stereotactic radiosurgery, or microsurgical nerve section. Our goal was to evaluate clinical outcomes after gamma knife radiosurgery (GKRS) in @entity1 with @entity15 with @entity4254 . METHODS: We evaluated clinical outcomes in 37 @entity1 with @entity4254 managed over a 12-year period. The maximum @entity4254 target dose varied between 70 and 90 Gy. Seventy-eight percent of @entity1 had failed prior surgery. In 9, GKRS was the first procedure. Median follow-up was 56.7 months (range, 6-174). @entity158 relief was assessed in each @entity1 by physicians who did not participate in the surgery. RESULTS: Eventual complete @entity158 relief (BNI grade I) after GKRS and reasonable @entity158 control (BNI grade I-IIIb) after GKRS were noted in 23 @entity1 (62.1%) and 36 @entity1 (97.3%) at some point in their course. Reasonable @entity158 control (BNI grade I-IIIb) after GKRS was maintained in 82.6%, 73.9%, and 54.0% of @entity1 after 1, 3, and 5 years. Fourteen @entity1 (37.8%) underwent a second or a subsequent procedure for residual or recurrent @entity158 . Eight @entity1 underwent a second GKRS, 5 underwent percutaneous @entity653 rhizotomy, and 1 underwent balloon microcompression. The complication rate after GKRS was 5.4% (new onset of nondisabling paresthesias). No @entity1 developed @entity809 . CONCLUSIONS: Gamma knife radiosurgery is the most minimally invasive surgical technique for @entity15 -related @entity4254 and has low morbidity. For this reason, gamma knife radiosurgery proved to be a satisfactory management strategy for @entity15 -related @entity4254 .

title: Gamma knife radiosurgery for @entity15 -related XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity4254 :: ('MESH:D014277', 'Disease') :: ['TN', 'trigeminal neuralgia']

entities_list: @entity809 :: ('MESH:D010292', 'Disease') :: ['dysesthesias']

entities_list: @entity653 :: ('MESH:D005990', 'Chemical') :: ['glycerol']

entities_list: @entity2531 :: ('MESH:D013001', 'Disease') :: ['pain disorder']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'multiple sclerosis']

answer: @entity4254 :: (MESH:D014277,Disease) :: ['trigeminal neuralgia']


abstract: @entity9933 is a rare @entity600 that usually is fatal. This report describes our experience in two such cases. In both cases, the diagnosis was suspected at birth, because the @entity1 had @entity649 without an audible cry and were difficult to intubate. A gastrostomy and banding of the abdominal esophagus provided effective initial stabilization, in conjugation with respiratory management. The first @entity1 also had @entity299 , and the @entity1 died of @entity712 1 week after birth. The second @entity1 , who had @entity9933 with a proximal @entity4501 and a @entity292 , was managed successfully. At 9 months of age, a tracheotomy was performed, a long T tube was inserted to maintain the airway patency beyond the proximal @entity4501 , and the @entity1 was discharged. At 3 years of age, esophageal reconstruction was performed with a colonic interposition graft. The @entity1 is thriving and developing normally at 4 years of age. Diagnosis at birth and maintenance of airway patency are essential for successful management of @entity9933 . Initial surgical interventions are palliative but lifesaving. Subsequent management focuses on improving the quality of life and allowing swallowing and speech.

title: Surgical management of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'infant']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['cardiac failure']

entities_list: @entity4501 :: ('MESH:D014138', 'Disease') :: ['tracheoesophageal fistula']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['respiratory distress']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['congenital malformation']

entities_list: @entity292 :: ('MESH:D005402', 'Disease') :: ['bronchoesophageal fistula']

entities_list: @entity9933 :: ('MESH:C536975', 'Disease') :: ['tracheal agenesis', 'Tracheal agenesis']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['complex cardiac malformations']

answer: @entity9933 :: (MESH:C536975,Disease) :: ['tracheal agenesis']


abstract: OBJECTIVES: To validate the performance of percentage of free @entity1486 (%fPSA) in @entity1 undergoing extended scheme biopsy. The current cutoff values for %fPSA were chosen using data from sextant biopsies, which have been known to miss a significant number of @entity263 cases. Additionally, we sought to validate the use of %fPSA in @entity1 with a total PSA < 4.0 ng/mL or > 10.0 ng/mL. METHODS: We evaluated %fPSA performance in 1077 @entity1 who had undergone initial extended prostate biopsy. The @entity1 were categorized according to their PSA level into 2 groups (>4.0 and  <=4.0) ng/mL. RESULTS: The overall @entity5 detection rate was 42.1%. The mean PSA level was 7.6 ng/mL, and the mean %fPSA was 18.0%. The area under the curve for %fPSA was 0.59 (95% confidence interval 0.57-0.61) for all PSA levels, comparable to previous reports from sextant biopsy series. The performance of %fPSA in predicting @entity263 on initial extended biopsy was improved with a PSA level of  <=4.0 ng/mL (area under the curve 0.66, 95% confidence interval 0.62-0.70) compared with a PSA level >4.0 ng/mL (area under the curve 0.57, 95% confidence interval 0.55-0.59; P < .001). A specificity of 85% was achieved for a %fPSA cutoff of 11% for the  <=4.0-ng/mL group and 10% for the >4.0-ng/mL group. CONCLUSIONS: The performance of %fPSA in predicting the presence of @entity263 was not altered when an extended biopsy scheme was used. Although a %fPSA level greater than our cutoffs would not rule out @entity263 , a low %fPSA would be particularly useful in predicting @entity263 , especially in @entity1 with normal digital rectal examination findings and a PSA level <4 ng/mL.

title: Percentage of free XXXX : implications in modern extended scheme prostate biopsy.

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']

answer: @entity1486 :: (354,Gene) :: ['prostate-specific antigen']


abstract: @entity5243 are a class of compounds utilized extensively in widely-distributed consumer goods, and have been associated with various adverse health outcomes in previous epidemiologic research. Some of these health outcomes may be the result of @entity5244 -induced increases in oxidative stress or @entity32 , which have been demonstrated in animal studies. The aim of this study was to explore the relationship between urinary @entity5244 metabolite concentrations and serum markers of @entity32 and oxidative stress (C-reactive protein (CRP) and gamma glutamyltransferase (GGT), respectively). Subjects were @entity1 in the National Health and Nutrition Examination Survey (NHANES) between the years 1999 and 2006. In multivariable linear regression models, we observed significant positive associations between CRP and @entity5245 (MBzP) and @entity5246 (MiBP). There were CRP elevations of 6.0% (95% confidence interval (CI) 1.7-10.8%) and 8.3% (95% CI 2.9-14.0%) in relation to interquartile range (IQR) increases in urinary MBzP and MiBP, respectively. GGT was positively associated with @entity5247 ( @entity5247 ) and an @entity5247 % variable calculated from the proportion of @entity5247 in comparison to other @entity5248 ( @entity5248 ) metabolites. IQR increases in @entity5247 and @entity5247 % were associated with 2.5% (95% CI 0.2-4.8%) and 3.7% (95% CI 1.7-5.7%) increases in GGT, respectively. CRP and GGT were also inversely related to several @entity5244 metabolites, primarily oxidized metabolites. In conclusion, several phthalate monoester metabolites that are detected in a high proportion of urine samples from the US general population are associated with increased serum markers of @entity32 and oxidative stress. On the other hand, several oxidized phthalate metabolites were inversely associated with these markers. These relationships deserve further exploration in both experimental and observational studies.

title: Urinary @entity5244 metabolites in relation to biomarkers of XXXX and oxidative stress: NHANES 1999-2006.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity5247 :: ('MESH:C016599', 'Chemical') :: ['MEHP', 'mono(2-ethylhexyl) phthalate']

entities_list: @entity5245 :: ('MESH:C103325', 'Chemical') :: ['mono-benzyl phthalate']

entities_list: @entity5248 :: ('MESH:D004051', 'Chemical') :: ['DEHP', 'di(2-ethylhexyl) phthalate']

entities_list: @entity5244 :: ('MESH:C032279', 'Chemical') :: ['phthalate']

entities_list: @entity5246 :: ('MESH:C575690', 'Chemical') :: ['mono-isobutyl phthalate']

entities_list: @entity5243 :: ('CHEBI:35484', 'Chemical') :: ['Phthalate esters']

answer: @entity32 :: (MESH:D007249,Disease) :: ['inflammation']


abstract: OBJECTIVES: During normal left ventricular (LV) filling, a vortex ring structure is formed distal to the left atrioventricular valve (LAVV). Vortex structures contribute to efficient flow organization. We aimed to investigate whether @entity340 in @entity1 with a corrected @entity474 ( @entity474 ) has an impact on vortex ring formation. METHODS: Whole-heart 4D flow MRI was performed in 32 @entity1 (age: 26      12  years), and 30 healthy subjects (age: 25      14  years). Vortex ring cores were detected at peak early (E-peak) and peak late filling (A-peak). When present, the 3-dimensional position and orientation of the vortex ring was defined, and the circularity index was calculated. Through-plane flow over the LAVV, and the vortex formation time (VFT), were quantified to analyze the relationship of vortex flow with the inflow jet. RESULTS: Absence of a vortex ring during E-peak (healthy subjects 0%, vs @entity1 19%; P  =  .015), and A-peak (healthy subjects 10% vs @entity1 44%; P  =  .008) was more frequent in @entity1 . In 4 @entity1 , this was accompanied by a high VFT (5.1-7.8 vs 2.4      0.6 in healthy subjects), and in another 2 @entity1 with abnormal valve anatomy. In @entity1 compared with controls, the vortex cores had a more-anterior and apical position, closer to the ventricular wall, with a more-elliptical shape and oblique orientation. The shape of the vortex core closely resembled the valve shape, and its orientation was related to the LV inflow direction. CONCLUSIONS: This study quantitatively shows the influence of abnormal LAVV and LV inflow on 3D vortex ring formation during LV inflow in @entity1 with corrected @entity474 , compared with healthy subjects.

title: Altered left ventricular vortex ring formation by 4-dimensional flow magnetic resonance imaging after repair of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['LAVV abnormality']

entities_list: @entity474 :: ('MESH:C562831', 'Disease') :: ['atrioventricular septal defect', 'AVSD']

answer: @entity474 :: (MESH:C562831,Disease) :: ['atrioventricular septal defects']


abstract: Lantang @entity1707 (16 sows), which is one of the south China type @entity1707 breeds, was crossed with Landrace @entity1707 (8 boars) to construct the resource population. According to the @entity1707 linkage map of USDA-MARC2.0, 31 microsatellite DNA markers on @entity1707 chromosomes 1, 4, 7, and 8 were used to genotype the parents F1 and F2. The distance between adjacent markers was about 10 to 20 cM. The gene frequency, heterozygosity (h), and @entity12605 ( @entity12605 ) were calculated. The marker genotype of parents, F1, and F2 were obtained with WAVEO @entity377 fragment analysis system (DHPLC) and ABI 377 DNA sequencer. Twenty-one microsatellite markers on chromosomes 1, 4, and 8 were genotyped with ABI 377. The length of the DNA fragments of 18 alleles on 13 microsatellite markers were beyond the range reported on the web site. The loci of new alleles were 62% of total markers. The heterozygosities of the 31 microsatellite ranged from 0.043 to 0.7855, the heterozygosities of 70% loci were over 0.6, the average heterozygosity was 0.6460. The average @entity12605 ( @entity12605 ) of 31 microsatellite markers was 0.5949, the @entity12605 of 77.4% loci were over 0.5. The values of h and @entity12605 suggested that polymorphism information of these markers in the resource population was plentiful. These markers could be used to map quantitative traits loci of important economic traits in this population.

title: [Analysis of microsatellite markers on four chromosomes in F2 design XXXX resource family].

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

entities_list: @entity12605 :: ('MESH:D063466', 'Disease') :: ['polymorphism information content', 'PIC']

answer: @entity1707 :: (9823,Species) :: ['pig']


abstract: During a 3-year period, 12,158 cardiac catheterizations were performed via the brachial artery. During this same period, 106 @entity1 were operated on for complications of @entity1317 and/or @entity715 , an incidence of 0.9%. The indication for the cardiac catheterization was @entity453 in almost 92% of the @entity1 . Early (less than 4 days) brachial artery repair was done in 90% of the @entity1 . The operative findings were @entity715 (91%), @entity130 (54%), @entity850 (13%), laceration and/or perforation (11%), and @entity731 (6%). Because of @entity130 , localized resection was done in two thirds of the @entity1 . Vascular continuity was obtained with axial reanastomosis in 45 @entity1 and interposition vein graft in 26 @entity1 . Primary lateral repair was performed in 23 @entity1 (22%). Ninety-five percent (101 @entity1 ) had initial excellent results. Of the five @entity1 who required reoperation, flow was restored in four @entity1 . Thus, 99% of @entity1 had restoration of a patent brachial artery. Contributing factors for @entity455 are "redo" catheterization, prolonged catheterization time, catheter change, brachial artery @entity731 , improper arteriotomy closure, experience of cardiologist, female @entity1 , and failure to use heparin. Because of the unpredictability of @entity63 symptoms occurring after @entity715 , the need for bypass graft surgery when delayed, and the good results with early surgical intervention, early exploration of @entity455 after cardiac catheterization and appropriate repair are recommended.

title: XXXX after cardiac catheterization.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['brachial artery complications']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis', 'atherosclerotic plaque']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity1317 :: ('MESH:D057772', 'Disease') :: ['brachial artery injury']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'brachial artery thrombosis']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['intimal injury', 'vessel injury']

answer: @entity1317 :: (MESH:D057772,Disease) :: ['Brachial artery injury']


abstract: PURPOSE: This study was designed to evaluate functional outcome in @entity1 treated with preoperative radiotherapy after low anterior resection and a coloanal @entity254 for @entity5 . METHODS: Functional outcome data from @entity1 enrolled in a prospective randomized trial comparing 3 reconstructive procedures were evaluated with respect to administration of preoperative radiotherapy. @entity322 was assessed with a questionnaire on bowel function including the @entity1241 Severity Index; sexual function was assessed with the Sexual Health Inventory for @entity1 and a gender-specific questionnaire for @entity1 . Quality of life was assessed with SF-36 scores. RESULTS: Of 364 @entity1 enrolled, 153 (42%) had no radiotherapy or chemotherapy, and 211 (58%) had preoperative radiotherapy; 186 (51%) had chemotherapy in addition to radiotherapy. Comparison of irradiated vs. nonirradiated @entity1 showed no significant differences in postoperative morbidity (29.9% vs. 35.3%; P = 0.27). Two-year follow-up of 297 @entity1 showed greater @entity73 in irradiated @entity1 (n = 170) vs. nonirradiated @entity1 (n = 127): e.g., mean number of daily bowel movements at 12 months, 4.2 +/- 3.5 vs. 3.5 +/- 2.6, P = 0.032; urgency, 85% vs. 67%, P = 0.002). Antidiarrheal use was significantly higher in irradiated @entity1 vs. nonirradiated @entity1 at 4 (P = 0.043), 12 (P = 0.002), and 24 (P = 0.001) months. Sexual Health Inventory for @entity1 scores indicated poorer function in irradiated @entity1 at 24 months (P = 0.039). Preoperative radiotherapy had no deleterious effects on quality of life. Multivariate analyses showed that negative effects of preoperative radiotherapy on urgency at 4 months (P = 0.002) and antidiarrheal use at 24 months were independent of reconstruction technique, but a positive effect of reconstruction with a @entity2418 was still observed in @entity1 who received radiotherapy. CONCLUSION: Preoperative radiotherapy does not increase overall morbidity but is associated with poorer functional outcome after low anterior resection with coloanal @entity254 . Preoperative radiotherapy and the @entity2418 are nonconfounding predictors of functional outcome up to 24 months after surgery.

title: Preoperative radiotherapy is associated with worse functional results after coloanal XXXX for @entity5 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Men']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['Incontinence']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['low rectal cancer']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impairment of bowel function']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity1241 :: ('MESH:D005242', 'Disease') :: ['Fecal Incontinence']

answer: @entity254 :: (MESH:C563598,Disease) :: ['anastomosis']


abstract: To measure the effects of dietary fat on feedlot performance, carcass characteristics, and beef appearance, moisture binding, shelf life, and @entity2419 , 168 crossbred beef steers (317 +/- 1.0 kg) were allotted randomly, within @entity616 , to a randomized complete block design with a 3 x2 + 1 factorial arrangement of dietary treatments. Main effects were level of yellow restaurant grease (RG; 0, 3, or 6%) and level of @entity2023 ( @entity2023 ; 3.5 or 7%), with the added treatment of 6% tallow and 7% @entity2023 in @entity2247 -based diets containing 15% @entity415 by-product and 7% supplement fed for 165 d (all dietary levels on a @entity3918 basis). Dietary treatment did not (P >0.10) affect DMI, LM area, beef brightness, or beef texture. Level of RG linearly increased (P <0.05) ADG from 1.48 to 1.60 kg/d, diet NE(m) from 2.4 to 2.6 Mcal/kg, diet NE(g) from 1.7 to 1.9 Mcal/kg, and internal fat from 2.1 to 2.4%. Level of RG linearly increased (P <0.05) G:F from 0.184 to 0.202, but decreased (P <0.05) beef firmness score from 3.0 to 2.8 and fat luster score from 3.1 to 2.8. Level of @entity2023 did not (P >0.10) affect any of the measurements; however, @entity2023 interacted with level of RG on fat thickness and yield grade (linear; P <0.05), as well as marbling score and percentage of carcasses grading USDA Choice (quadratic; P <0.05). Fat thickness and yield grade increased with increasing RG level in 3.5%, but not in 7%, @entity2023 diets. In steers fed 3.5% RG, marbling scores and percentage of carcasses grading Choice were greatest when fed with 3.5% @entity2023 , and least when fed 7% @entity2023 . Steers fed tallow had lower marbling scores (P = 0.01) and percentage of carcasses grading Choice (P = 0.066) than those fed RG. Retail storage attributes, including visual and instrumental color, decreased during storage (P <0.01), but were not (P >0.10) affected by diet. Trained sensory panel scores for initial tenderness increased quadratically (P = 0.07) as dietary RG increased, but diet did not (P >0.10) affect @entity393 , @entity393 , or trained sensory panel scores for sustained tenderness, initial and sustained juiciness, and beef flavor. Therefore, RG increased diet energy, improved performance, and increased carcass @entity1386 ; however, dietary fat and @entity2023 did not affect most measurements of water retention, color stability, or @entity2419 of beef.

title: Effects of supplemental fat on growth performance and quality of beef from steers fed @entity2247 - @entity415 product finishing diets: I. Feedlot performance, carcass traits, appearance, water binding, retail storage, and XXXX attributes.

entities_list: @entity2023 :: ('MESH:D006255', 'Disease') :: ['alfalfa hay', 'AH']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['drip loss', 'cooking loss']

entities_list: @entity2419 :: ('MESH:D002972', 'Disease') :: ['palatability']

entities_list: @entity616 :: ('MESH:D006327', 'Disease') :: ['weight blocks']

answer: @entity2419 :: (MESH:D002972,Disease) :: ['palatability']


abstract: BACKGROUND: @entity2956 ( @entity2956 ) such as @entity158 , joint sounds, and @entity717 are common, and magnetic resonance imaging (MRI) is now the method of choice for diagnostic assessment. PURPOSE: To describe MR criteria chosen and the amount of @entity1348 ( @entity1348 ) pathology registered when examining MR images from @entity1 referred to a university hospital for imaging of their TMJs. MATERIAL AND METHODS: The TMJs of 152 consecutive @entity1 , 102 @entity1 and 40 @entity1 , referred for MRI during an 18 month period were imaged with a 1.5 T imaging system. Twelve asymptomatic students, seven @entity1 and five @entity1 , gave informed consent and acted as a control group. RESULTS: Moderate to extensive disk displacement was registered in 53% of the @entity1    TMJs, and 38% of the disks were deformed. Degenerative changes registered were flattening of the condyle heads in 50% of the TMJs and erosion of their cortical surfaces in 30%. Osteophytes were present in 31% of the condyles and @entity236 in 30%. Marked to extensive effusion in synovial compartments was registered in 39% of the studied TMJs. In the control group, none of the TMJs showed anterior disk displacement, deformed disks or degenerative changes, but 8 of the 24 joints showed marked effusion. A tendency for a higher amount of disk displacement and deformation was seen among young age groups and more degenerative changes in older age groups, but differences among groups were not significant when tested with chi-square analysis. CONCLUSION: Defined MR criteria that allow for comparative assessment are presented. According to these criteria, a large proportion of the @entity1 referred for MR examination showed morphologic changes indicating @entity1348 pathology.

title: A practical approach to interpretation of MRI of the XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity2956 :: ('MESH:D013705', 'Disease') :: ['Temporomandibular disorders', 'TMDs']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow edema']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['impaired movement']

entities_list: @entity1348 :: ('MESH:D013706', 'Disease') :: ['TMJ', 'temporomandibular joint']

answer: @entity1348 :: (MESH:D013706,Disease) :: ['temporomandibular joint']


abstract: Tumour @entity39 factor-alpha ( @entity310 ) and @entity1356 ( @entity1356 ) are the central mediators in the genesis of @entity295 . The proinflammatory effects of these cytokines are counteracted in vivo by natural inhibitors. Soluble @entity310 receptors (sTNFR) are shed upon inflammatory stimuli such as @entity1356 and @entity310 itself. Circulating @entity310 can be complexed by these receptors, thus preventing @entity310 from binding to effector cells. The binding of @entity1356 to its receptor can be blocked by high concentrations of @entity1193 ( @entity1193 ), which is produced and released upon nearly the same stimuli as @entity1356 . This review presents some aspects of the kinetic behaviour of native sTNFR and of the production of native @entity1193 during severe @entity281 . It appears that in fulminant @entity295 , the plasma concentration of @entity310 is increased only transiently, during the very early stage of the @entity281 . The concentration of sTNFR, in contrast, remains elevated much longer, probably due to a slower clearance. During the acute stage of severe @entity166 , peripheral blood cells cannot be stimulated to produce @entity1356 . The production of @entity1193 , in contrast, is not affected. Thus, the kinetic behaviour and regulation of @entity310 and @entity1356 , is different from that of their antiinflammatory counterparts.

title: Kinetics of tumour @entity39 factor-alpha, soluble tumour XXXX factor receptors, @entity1356 and its receptor antagonist during serious @entity281 .

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis', 'septicaemia']

entities_list: @entity1356 :: ('3553', 'Gene') :: ['interleukin-1 beta', 'IL-1 beta']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity1193 :: ('3557', 'Gene') :: ['IL-1 Ra', 'interleukin-1 receptor antagonist', 'IL-1Ra']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'infections']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious diseases']

answer: @entity39 :: (MESH:D009336,Disease) :: ['necrosis']


abstract: @entity11184 ( @entity11184 ) has been shown to be the major mediator of @entity2741 of @entity5 , but may also exert effects on cell growth and differentiation. The @entity8302 H-500, when implanted in Fischer @entity35 , produces abundant @entity11184 and eventually causes the death of the host animal. In the present study we have used antisense RNA technology to block the effects of @entity11184 in H-500 @entity5 cells in vivo. The full-length @entity35 @entity11184 complementary DNA encoding @entity535 -36-->141 was subcloned as an EcoRI-BglII insert in the antisense orientation into the @entity1 expression vector pRc/ @entity2834 to produce the plasmid pRc-PAS. This plasmid was then stably transfected into the H-500 @entity5 cells with a Lipofectin reagent. After selection with the @entity5154 derivative @entity11185 , a stable cell line, H-500- @entity11184 -AS, was obtained which showed 80% inhibition of endogenous @entity11184 messenger RNA compared to wild-type or vector-only transfected H-500 cells. Conditioned culture medium from these experimental cells showed a marked decrease in @entity11184 immunoreactivity and in the ability of the medium to stimulate adenylate cyclase in UMR-106 @entity35 @entity421 cells. Furthermore, inhibition of @entity11184 production resulted in a significant increase in the doubling time of the H-500 cells. Transfection of the experimental plasmid into @entity35 -2 fibroblasts, which do not produce @entity11184 , had no effect on cell growth. Control and experimental cells were then implanted sc into male Fischer @entity35 . Animals were killed at timed intervals, and their @entity5 volumes were determined. Experimental animals receiving cells transfected with antisense @entity11184 plasmid showed near-normal levels of plasma @entity460 and decreased expression of tumoral @entity11184 messenger RNA. These animals also showed a 30-70% lower @entity5 volume during the course of the experiment compared to control animals. These studies have demonstrated that @entity11184 can play a role as a promoter of @entity5 growth in vitro and in vivo.

title: Regulation in vivo of the growth of XXXX by antisense ribonucleic acid for parathyroid hormone-related peptide.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian']

entities_list: @entity2741 :: ('MESH:D006934', 'Disease') :: ['hypercalcemia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Leydig tumor', 'malignancy']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity8302 :: ('MESH:D007984', 'Disease') :: ['Leydig cell tumor']

entities_list: @entity421 :: ('MESH:D012516', 'Disease') :: ['osteosarcoma']

entities_list: @entity5154 :: ('MESH:D009355', 'Chemical') :: ['neomycin']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity8302 :: (MESH:D007984,Disease) :: ['Leydig cell tumors']


abstract: AIM: The pseudo- @entity8990 has been associated with a variety of primary @entity74 , @entity281 and drugs. Recently, the development of dysgranulopoiesis characterised by a pseudo-PH @entity154 has been reported in two @entity1 with the use of @entity618 ( @entity2098 ) in the setting of heart and/or lung transplantation. We present a further five cases of @entity2098 -related dysgranulopoiesis characterised by a pseudo-PH @entity154 occurring after renal transplantation. METHODS: All @entity1 were receiving standard immunosuppression protocols for renal transplantation, including a combination of @entity2098 , @entity230 and either @entity205 or @entity1140 . Oral @entity4540 was also used for cytomegalovirus prophylaxis in each case. RESULTS: Development of @entity6349 occurred a median of 96 days (range 66-196 days) after transplantation. Moderate or severe neutropaenia (<1.0 x 10(9)/l) developed in three cases, and appeared to be directly correlated with the percentage of circulating neutrophils present with @entity6349 morphology. Resolution of dysgranulopoiesis occurred in all cases only after dose reduction and/ or cessation of both @entity2098 and @entity4540 . CONCLUSIONS: In our series, the observed @entity6349 appeared related to the combination of @entity2098 and @entity4540 , rather than @entity2098 alone. Further study is required to determine the exact incidence and pathogenesis of this pattern of @entity236 .

title: Neutrophil dysplasia characterised by a @entity8990 occurring with the use of XXXX and @entity4540 following renal transplantation: a report of five cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8990 :: ('MESH:D010381', 'Disease') :: ['Pelger-Huet (PH) anomaly']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow toxicity']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin']

entities_list: @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['haematological disorders']

entities_list: @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity4540 :: ('MESH:D015774', 'Chemical') :: ['ganciclovir']

entities_list: @entity6349 :: ('MESH:D004416', 'Disease') :: ['dysplastic granulopoiesis', 'dysplastic']

answer: @entity618 :: (MESH:C063008,Chemical) :: ['mycophenolate mofetil']


abstract: Fetal @entity5 are rare. We present a case of intrauterine diagnosis of a diaphragmatic @entity5 presenting with fetal hydrops at 32 weeks' gestation. The sonographic findings were bilateral pleural effusion, @entity843 and @entity4 . A large right-sided diaphragmatic @entity5 was identified. Owing to the findings on ultrasound and magnetic resonance imaging a solid @entity5 was suspected. The @entity1143 were drained and malignant cells identified. Because of rapid @entity5 progression Cesarean section was performed and a hydropic female newborn was delivered at 34 + 0 weeks' gestation. There was no sign of @entity3 . @entity5 biopsy revealed an @entity3943 . Therapy included chemotherapy and secondary surgical intervention. After a good primary response with complete remission after 6 months, the @entity980 relapsed at 12 months with cerebral metastasis. The prognosis was poor.

title: Prenatal management of diaphragmatic XXXX presenting with fetal hydrops.

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusions']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignant tumors', 'Postnatally tumor', 'malignant tumor']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['skin edema']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']

entities_list: @entity980 :: ('MESH:D012208', 'Disease') :: ['rhabdomyosarcoma']

entities_list: @entity3943 :: ('MESH:D018232', 'Disease') :: ['alveolar rhabdomyosarcoma']

answer: @entity980 :: (MESH:D012208,Disease) :: ['rhabdomyosarcoma']


abstract: PURPOSE: Off-hours admissions have been associated with an increased risk of poor outcomes but results have been inconsistent, possibly due to different measures of off-hours care used. We examined, using a single condition and increasingly refined definitions of time of admission, the effect of off-hours admissions on 7-day @entity64 case-fatality. METHODS: We studied a retrospective cohort of 82,219 @entity64 admissions to 115 Dutch hospitals between 2000 and 2004. Data were from the Dutch Medical Register and analysed using multivariable multilevel logistic regression. We adjusted for variables such as age, gender, Charlson-Deyo comorbidity score, urgency of admission, hospital teaching status and speciality of attending physician. RESULTS: After adjustment, we observed higher 7-day @entity204 risk for weekend admissions when compared to weekday admissions (OR 1.27; 95% CI 1.20 to 1.34). Sunday displayed the highest risk of @entity204 (OR 1.31; 95% CI 1.20 to 1.44). With the Monday day-shift as a reference, the @entity204 odds were increased during the Sunday and Saturday day-shifts, the evening-shifts on Sunday and Monday, and during all night-shifts. The night-shift ORs ranged from 1.94 (95% CI 1.56 to 2.41) to 2.14 (95% CI 1.74 to 2.63). When compared to admission at 8:00 we observed increased @entity204 odds from midnight until 7:00 and decreased @entity204 odds from 14:00 until 18:00. CONCLUSIONS: Weekends represent a period of increased @entity204 risk for @entity64 @entity1 in the Netherlands. However, this increased risk appears to represent an exacerbation of an underlying night-time risk present during the weekdays.

title: A multifaceted look at time of admission and its impact on case-fatality among a cohort of XXXX @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'ischaemic stroke']

answer: @entity64 :: (MESH:D020521,Disease) :: ['ischaemic stroke']


abstract: Despite advances in prevention, fall-related hospitalisation rates among older @entity1 are still increasing. Rates between 1998/1999 and 2008/2009 for non-facture-related injuries increased by 6.1% while @entity174 injuries declined by -0.4%. Varying trends in rates of different @entity130 makes it difficult to provide a definitive explanation for these changes. INTRODUCTION: Despite advances in fall prevention research and practice, the rate of fall-related hospitalisations continues to increase. However, hip @entity174 rates appear to be declining. An examination of trends in types of injuries that contribute to the @entity130 rate is required to establish which injuries are driving the falls admission rate. The aim of this paper is to examine trends in fall-related injury hospital admissions by @entity130 in New South Wales (NSW), Australia. METHODS: A retrospective review of fall-related @entity130 in NSW among individuals aged 65+   years, by @entity130 , was conducted from 1 July 1998 to 30 June 2009. Direct age-standardised admission rates were calculated. Negative binomial regression was used to examine the statistical significance of changes in trend over time of different hospitalised fall-related injuries. RESULTS: The fall-related hospitalisation rate increased by 1.7% each year (p   <   0.0001; 95% confidence interval (CI), 1.3-2.1%). However, the rate of @entity174 declined by -0.4% (p   <   0.03; 95% CI, -0.8-0.0%); whereas, the non- @entity174 rate increased by 6.1% (p   <   0.0001; 95% CI, 5.5-6.7%) annually. Rates for severe @entity542 , rib and @entity174 increased while those for hip and @entity174 declined. CONCLUSIONS: It appears that while fall prevention efforts in NSW are not yet affecting the overall rate of @entity130 , there has been a significant decline in the rates of some @entity174 . Opposing trends in the rates of other @entity174 admissions and a significant increase in the rate of non- @entity174 injuries associated with falls makes a definitive explanation for these changes difficult.

title: Conflicting trends in fall-related XXXX among older @entity1 : variations by @entity130 .

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['injury hospitalisations', 'injury types', 'overall fall injury', 'injury type', 'injury hospitalisation']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['head injuries']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'forearm fracture', 'pelvic fracture', 'fracture']

answer: @entity130 :: (MESH:D014947,Disease) :: ['injury hospitalisations']


abstract: The study was set up to investigate factors delaying treatment of @entity583 . Nine hundred and sixty-seven Austrian physicians submitted data on their most recent case of @entity583 in a cross-sectional study. Mean time for seeking medical care was 111 min from onset; mean admission time to the hospital was 136 min. The degree of @entity148 and fear perceived by the @entity1 was positively associated with an earlier decision. Adjusted means of decision time according to degree of fear ranged from 29 to 133 min, adjusted means of admission time from 77 to 153 min. Decision time and admission time were negatively associated with the presence of typical symptoms and a history of @entity583 . Adjusted means of decision time according to symptom-history category ranged from 75 to 134 min, adjusted means of admission time from 110 to 151 min. Admission time was also higher in @entity1 when @entity1 lived alone, and if the journey to the hospital was a 40 min or more car drive (i.e. 90th percentile). We conclude that measures that increase awareness in @entity1 at risk are vital to reduce delays in seeking medical care and hospital admission, and thus to improve the prognosis of @entity583 .

title: Factors delaying treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'acute myocardial infarction']

answer: @entity583 :: (MESH:D009203,Disease) :: ['acute myocardial infarction']


abstract: AIMS: @entity3957 ( @entity3958 ) ameliorates @entity299 in several models by suppressing endoplasmic reticulum (ER) stress. Endothelial-to-mesenchymal transition (EndMT) is implicated in the development of @entity299 . Therefore, we investigated whether @entity3958 could attenuate EndMT by suppressing ER stress. MAIN METHODS: ER stress was induced by @entity2425 (TM) and @entity2426 (TG) and inhibited by @entity10022 ( @entity10023 ) in @entity1 umbilical vein endothelial cells (HUVECs). ER stress and EndMT were measured by Western blot, Real-Time PCR and immunofluorescence staining. Inhibition smad 2 and @entity7242 pathway were performed by specific inhibitors and siRNA. Ultrastructural examination was detected by transmission electron microscope. The functions of HUVECs were investigated by cell migration assay and tube formation in vitro. KEY FINDINGS: Under ER stress, the expression of endothelial marker @entity2279 significantly decreased while mesenchymal markers a-SMA, @entity2277 and collagen 1 increased which could be inhibited by @entity10023 . Moreover, HUVECs changed into a fibroblast-like appearance with the activation of @entity2536 and @entity7242 kinase pathway. After inhibiting @entity7242 pathway, EndMT would be significantly inhibited. TM reduced @entity3958 levels in cell lysate and @entity3958 pretreatment could preserve endothelial cell appearance with decreased ER stress and ameliorated dilation of ER. @entity3958 could also downregulate the mesenchymal markers expression, and upregulate the endothelial markers expression, accompanied with the suppression of @entity7242 pathway. Moreover, @entity3958 partially restored the capacity of migration and tube formation in HUVECs. SIGNIFICANCE: These results revealed that @entity3958 could protect against ER stress-induced EndMT through @entity7242 pathway, which may be a novel role for the cardioprotection of @entity3958 .

title: @entity3957 suppresses endoplasmic reticulum stress-induced endothelial-to-mesenchymal transition through XXXX pathway.

entities_list: @entity2426 :: ('MESH:D019284', 'Chemical') :: ['thapsigargin']

entities_list: @entity2425 :: ('MESH:D014415', 'Chemical') :: ['tunicamycin']

entities_list: @entity10022 :: ('MESH:C075773', 'Chemical') :: ['4-phenylbutyrate']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac fibrosis']

entities_list: @entity3957 :: ('MESH:D006862', 'Chemical') :: ['Hydrogen sulfide']

answer: @entity7242 :: (6714,Gene) :: ['src']


abstract: BACKGROUND: @entity3610 ( @entity3610 ) is a common cause of @entity249 , especially in the morbidly @entity28 . We evaluated the long-term effects of Roux-en-Y gastric bypass on @entity3610 and @entity249 . METHODS: A total of 566 morbidly @entity28 @entity1 underwent Roux-en-Y gastric bypass from 2000 to 2009. A total of 31 @entity1 (5.5%) had a history of @entity3610 . Of the 31 @entity1 , 6 were postmenopausal and 5 lost to follow-up and were excluded. Telephone interviews were conducted with the 20 eligible @entity1 . RESULTS: The mean age and body mass index was 32    5.8 years (range 22-42) and 52.8    9.08 kg/m(2) (range 37-76) before surgery. All 20 @entity1 had >=  2 of 3 diagnostic criteria for @entity3610 , including clinical or biochemical evidence of @entity3206 , or @entity3610 . Of these, 85% had @entity2589 , 70% had @entity3427 , and 45% had @entity6 with medication. Before surgery, 8 @entity1 conceived with or without hormonal treatment, 2 did not desire pregnancy, and 10 did not conceive. The mean follow-up was 46.7 months. After surgical @entity353 , menstruation was corrected in 82%, @entity3427 had resolved in 29%, and 77.8% of those with @entity6 had complete remission. Of the 10 @entity1 who did not conceive before surgery, 4 no longer desired pregnancy, and the remaining 6 @entity1 had become pregnant within 3 years of surgery-5 without any hormonal treatment and 1 with in utero insemination. CONCLUSION: Surgical @entity353 after Roux-en-Y gastric bypass achieves excellent amelioration of @entity3610 manifestations and the postoperative conception rate in infertile @entity3610 subjects desiring pregnancy was 100%.

title: Roux-en-Y gastric bypass ameliorates XXXX and dramatically improves conception rates: a 9-year analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity3610 :: ('MESH:D011085', 'Disease') :: ['polycystic ovaries', 'Polycystic ovary syndrome', 'PCOS']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'type 2 diabetes mellitus']

entities_list: @entity3206 :: ('MESH:D000858', 'Disease') :: ['hyperandrogenism, anovulation']

entities_list: @entity2589 :: ('MESH:D009839', 'Disease') :: ['oligomenorrhea']

entities_list: @entity3427 :: ('MESH:D006628', 'Disease') :: ['hirsutism']

answer: @entity3610 :: (MESH:D011085,Disease) :: ['polycystic ovary syndrome']


abstract: OBJECTIVE: To assess the prevalence of @entity3492 ( @entity3492 ), @entity4700 ( @entity4700 ), and Pendred ( @entity6361 ) mutations in a population of adult cochlear implant @entity1 with a history of either early idiopathic or hereditary progressive @entity1274 . BACKGROUND: Significant efforts have been applied in defining the epidemiology of @entity3492 ( @entity3492 )-associated @entity393 in the pediatric population, yet the issue remains ambiguous for adult @entity1 . Causation is important in this population because there are implications to prognosis, risk of associated medical manifestations, and for genetic counseling purposes. @entity1 : Adult @entity1 meeting criteria for cochlear implantation with early-onset @entity393 assessed at an adult cochlear implant center from November 2007 to April 2009. INTERVENTION: Genomic DNA samples from whole blood were tested with bidirectional sequence analysis for mutations in the coding region of the @entity3492 and @entity6361 genes and tested for large deletions of the @entity4700 gene. RESULTS: Fifty-seven @entity1 were analyzed for @entity3492 mutations. Eight @entity1 (14%) were found to have @entity3492 -related @entity393 ; 5 @entity1 were homozygous for the @entity4701 mutation (genotype @entity4701 / @entity4701 ), and 3 additional @entity1 were compound heterozygotes with 2 different @entity3492 mutations. Of these 8 @entity1 with @entity3492 -related @entity393 , 3 had serviceable hearing into their teenage years. One additional @entity1 had 1 @entity3492 variant ( @entity25357 , heterozygous). None had @entity4700 mutations. Of the 57 @entity1 , 30 were also analyzed for @entity6361 mutations. Three of these @entity1 were compound heterozygotes for disease-causing @entity6361 mutations, confirming @entity6361 -related @entity393 . Three additional @entity1 were found to have a single variant in @entity6361 . CONCLUSION: The prevalence of @entity3492 - and @entity6361 -related @entity393 in an adult population with early-onset severe @entity1274 is significant, suggesting the need for routine assessment for genetic etiologies in this group. We also note 3 individuals with causal @entity3492 mutations with subjective serviceable hearing into adolescence in our cohort.

title: Prevalence of @entity3492 ( @entity3492 ) and Pendred ( XXXX ) mutations in a population of adult cochlear implant candidates.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity1274 :: ('MESH:D006319', 'Disease') :: ['sensorineural hearing loss', 'sensorineural deafness']

entities_list: @entity25357 :: ('p|SUB|M|195|I', 'ProteinMutation') :: ['p.Met195Ile']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss', 'hearing impairment']

answer: @entity6361 :: (5172,Gene) :: ['SLC26A4']


abstract: Possible modifications of the beta-adrenergic effector system during the development of @entity291 perirenal brown adipose tissue (BAT) in utero and its transformation into white-like adipose tissue after birth were studied. The parameters assessed were the level of expression of beta 1-, beta 2- and beta 3-adrenergic receptor (AR) mRNAs and the response of the plasma-membrane adenylate cyclase to @entity3044 and to the beta 3-agonist @entity3047 . The beta 3-AR mRNA was found to be expressed very early in utero, i.e. before the third month of foetal life. Then it increased dramatically (9-fold) between month 6 of foetal life and birth. A high beta 3-AR mRNA level was maintained after birth up to an age of 3 months. After conversion of BAT into white-like adipose tissue, i.e. in the adult @entity291 , the beta 3-AR mRNA expression became small or not detectable, and the beta 1-AR mRNA, which was expressed much less than the beta 3-AR mRNA in foetal life, became predominant. A response of the adenylate cyclase to @entity3044 was observed in foetal life (3.1-fold stimulation). It decreased after birth (1.8-fold stimulation) and then remained constant until adulthood. A response to @entity3047 was also observed in foetal life (1.8-fold stimulation). It was maintained after birth, but disappeared in the adult. A possible relationship between the beta-AR expression and the adenylate cyclase response to @entity3044 on the one hand and the uncoupling-protein expression on the other is discussed. The @entity291 might represent a good model to understand the transition from brown to white fat in the @entity1 .

title: Expression of beta 1- and beta 3-adrenergic-receptor messages and adenylate cyclase beta-adrenergic response in XXXX perirenal adipose tissue during its transformation from brown into white fat.

entities_list: @entity3044 :: ('MESH:D007545', 'Chemical') :: ['(-)-isoprenaline']

answer: @entity291 :: (9913,Species) :: ['bovine']


abstract: The aim of the study was to define the effects of daily hospice team's activities on @entity308 and @entity148 in @entity0 @entity1 having undergone mastectomy after three-month therapy. This prospective study included 35 @entity1 that underwent mastectomy for @entity0 , followed by 3-month treatment at daily hospice, Tuzla University Clinical Center. Control group consisted of 35 mastectomized @entity1 that did not visit daily hospice. @entity308 and @entity148 were estimated by use of Zung's scale. @entity1 were tested initially and retested at 12 weeks. On initial testing, the mean value of @entity308 was 59.85 +/- 6.97 in the study group and 55.65 +/- 7.91 in the control group. On three-month retesting, the level of @entity308 was lower in the study group, with a mean value of 48.57 +/- 7.06 (P<0.0001) (steam T-test and Wilcoxon's test) and higher in the control group, with a mean value of 60.45 +/- 7.47 (P=0.0001) (steam T-test and Wilcoxon's test). On initial testing, the mean value of @entity148 was 54.97 +/- 6.35 and 52.20 +/- 6.03 in the study and control group, respectively. On three-month retesting, the level of @entity148 was lower in the study group, with a mean value of 43.43 +/- 5.97 (P<0.0001), showing improvement from initial testing, but was higher in the control group, with a mean value of 55.68 +/- 7.47 (P=0.0002). In conclusion, daily hospice team's treatment had favorable effects on lowering the levels of @entity308 and @entity148 in @entity1 undergoing mastectomy for @entity0 .

title: Daily hospice: @entity308 and XXXX after mastectomy for @entity0 .

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression']

answer: @entity148 :: (MESH:D001008,Disease) :: ['anxiety']


abstract: BACKGROUND: For aortic arch surgery, the potential risks of @entity1167 with or without antegrade cerebral perfusion have been widely documented. We hereby describe our early experience with a "branch-first continuous perfusion" technique that, by avoiding @entity2332 and @entity1167 , has the potential to reduce morbidity and mortality. METHODS: Arterial perfusion is peripheral using femoral and axillary inflows. Disconnection of each arch branch, and @entity254 to the trifurcation graft, proceeds sequentially from the innominate to the left subclavian artery, with continuous perfusion of the heart and viscera by lower body and brain by upper body arterial return. After the descending aorta is clamped, the debranched arch may then be replaced and connected to the ascending aorta before the common stem of the trifurcation graft is joined to the arch graft. Thirty @entity1 underwent this technique. Twelve @entity1 were operated on for aortic dissection and the remainder for @entity439 . RESULTS: With experience, minimum pump temperature rose from 16  C to 34  C. There was 1 (3.3%) death, and 2 (6.7%) @entity1 had @entity51 . Extubation was achieved within 24 hours in 12 (40%) @entity1 , whereas 14 (47%) left the intensive care unit within 2 days. Ten (33%) @entity1 were discharged from the hospital within 7 days. Eight (27%) @entity1 required no transfusion of blood or blood products. CONCLUSIONS: This technique brings us closer to the goal of arch surgery without cerebral or visceral @entity1167 and the morbidity of @entity2332 . Early results are encouraging.

title: Branch-first aortic arch replacement with no @entity1167 or XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological dysfunction']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['deep hypothermic circulatory arrest', 'circulatory arrest']

entities_list: @entity2332 :: ('MESH:D007035', 'Disease') :: ['deep hypothermia']

answer: @entity2332 :: (MESH:D007035,Disease) :: ['deep hypothermia']


abstract: Forty-eight cases of host valve @entity884 and 24 cases of @entity340 occurring during a concurrent period of time were analyzed to assess differences between the two groups. The over-all incidence of @entity340 during this 40 month period was 4.4%. The symptoms and signs in both groups were similar, except that PVE @entity1 had more frequent occurrences of changing heart murmurs and @entity999 . Spleen scans may be helpful in the diagnosis of selected cases of culture-negative @entity340 . There was no significant difference between the two groups for the various infecting microorganisms. However, the culture-negative prosthetic valve group had a mortality rate of 77.7% compared to 46.2% for the host valve group. In the HVE @entity1 the oral cavity or urinary tract was the probable source of @entity281 in 50.0% of the @entity1 . In about one third of HVE cases, there was strong evidence that the @entity281 was related to a therapeutic procedure, whereas nearly half of the PVE @entity1 had clinical evidence of an @entity281 at the time of open-heart surgery. We emphasize the need for good pre- and postoperative surveillance to eliminate possible predisposing @entity281 and appropriate antibiotic prophylaxis in all @entity1 with @entity340 at times of risk. The survival rate in @entity1 with @entity340 was highest in those @entity1 who received "appropriate" antibiotics and, if significant @entity712 was present, surgical intervention was necessary.

title: A comparative study of 48 host valve and 24 XXXX cases.

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure']

entities_list: @entity999 :: ('MESH:D020766', 'Disease') :: ['splenic and cerebral emboli']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['extracardiac infection', 'infection', 'infections']

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['prosthetic valve endocarditis', 'valvular disease']

entities_list: @entity884 :: ('MESH:D004696', 'Disease') :: ['endocarditis']

answer: @entity340 :: (MESH:D006349,Disease) :: ['prosthetic valve endocarditis']


abstract: CONTEXT: Lumbar puncture (LP) is a common medical procedure for which no valid consensus exists in situations of @entity548 or @entity715 risk. The aim of this study was to identify the opinion-guided practices of LP at a national level. METHODS: A national opinion survey on Internet. An anonymous questionnaire of 19 questions collecting information about the LP practice for @entity1 with @entity548 or @entity715 risks. RESULTS: We sent 632 e-mails with the link of the survey and obtained 211 responses in six weeks. None of the responses was unanimous for any of the 13 different clinical situations proposed. Six practices were reported as adopted by the majority of @entity1 , six by more than one-third. Reports of practices were highly variable, particularly for the minimum platelets count accepted, for the management of @entity1 taking two antiplatelet agents or newer anticoagulant agents. DISCUSSION AND CONCLUSION: These results underline the heterogeneity of practices and the lack of recommendations. The establishment of a clear consensus in this area seems essential to guide practices in the future. In order to increase the representativeness of our responses, the survey is still going on online and will be open for all practitioners who wish to participate (http://www.surveymonkey.com/s/hemopl).

title: [Lumbar puncture practice in case of XXXX or ischemic risk: A national opinion survey.]

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhagic']

answer: @entity548 :: (MESH:D006470,Disease) :: ['hemorrhagic']


abstract: BACKGROUND: Brain metastases (BM) occur in up to 40% of @entity1149 ( @entity1149 ) @entity1 . This trial assessed the safety and efficacy of pemetrexed- @entity900 in this population. @entity1 AND METHODS: Chemonaive @entity1149 @entity1 with BM ineligible for (radio)surgery, performance status (PS) of 0 to 2, were eligible for up to six cycles of @entity900 75 mg/m(2) and pemetrexed 500 mg/m(2) every 3 weeks. Whole -brain radiotherapy was given in case of disease progression or at chemotherapy completion. Primary end point was objective response rate (RR) on BM. Secondary end points included extracerebral and overall RR, safety profile and survival. RESULTS: Forty-three @entity1 were enrolled. Initial characteristics were mean age 60.4 years; males 29; PS: 0 in 37.2%, 1 in 60.5% and 2 in 22.3% of @entity1 ; @entity420 in 36 @entity1 , large cell in 4 @entity1 (nonsquamous, 93%) and @entity957 in 3 @entity1 . Functional classification of neurological status was stage I/II 86.0%, III 2.3% and IV 11.6%. Grade 3-4 hematological toxic effects were @entity1398 , 11 @entity1 ( @entity1398 , 1 @entity1 ), and @entity417 , 6 @entity1 . Non-hematological toxic effects were grade 2 @entity293 , one @entity1 ; grade 3 @entity55 , two @entity1 ; and grade 3 hypoacousia, one @entity1 . Cerebral, extracerebral and overall RR by intent to treat analysis were 41.9%, 34.9% and 34.9%, respectively. Median survival time and time to progression were 7.4 and 4.0 months, respectively. CONCLUSION: Pemetrexed- @entity900 is an effective and well-tolerated regimen as first-line therapy for @entity1149 @entity1 with BM who always suffer a poor prognosis.

title: Pemetrexed and XXXX as first-line chemotherapy for advanced @entity1149 ( @entity1149 ) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous carcinoma']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary infection']

answer: @entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']


abstract: UNASSIGNED: Thyrotropin (TSH)-secreting @entity977 are exceedingly rare at the pediatric age and no cases of co-secretion with other pituitary hormones in these @entity5 have been described in this age range. We present a case of a monomorphous @entity977 that co-secreted TSH and GH in a pediatric @entity1 . A 13-year-old male presented with increasing height velocity (17.75  cm/year, 9.55SD), @entity353 , and @entity227 . Initial biochemical evaluations revealed @entity1378 . @entity977 compressing the surrounding structures was detected by magnetic resonance, and a transsphenoidal surgery was initially performed. Pathological examinations revealed an atypical, monomorphous plurihormonal @entity10914 lineage @entity5 with mixed features of silent subtype 3 @entity652 and acidophil stem cell @entity652 . In the postoperative period, @entity1378 recurred with high levels of both GH and @entity442 . In addition, due to @entity5 re-growth, a multimodality treatment plan was undertaken including surgery, @entity1943 analogs, and radiotherapy. We report the first pediatric case of a plurihormonal TSH- and GH-secreting @entity977 , further expanding the clinical manifestations of pediatric @entity977 . Comprehensive pathological evaluation and close follow-up surveillance are crucial to the prompt delivery of the best therapeutic options in the context of this particularly aggressive @entity977 .

title: Monomorphous Plurihormonal Pituitary Adenoma of @entity10914 Lineage in a Giant Adolescent with Central XXXX .

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual impairment']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity1378 :: ('MESH:D006980', 'Disease') :: ['secondary hyperthyroidism']

entities_list: @entity977 :: ('MESH:D010911', 'Disease') :: ['plurihormonal pituitary adenoma', 'A giant pituitary tumor', 'pituitary tumor', 'pituitary adenomas', 'pituitary tumors', 'pituitary adenoma']

entities_list: @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin']

answer: @entity1378 :: (MESH:D006980,Disease) :: ['Hyperthyroidism']


abstract: OBJECTIVES: The high prevalence of @entity146 ( @entity146 ) in @entity1 with @entity4225 ( @entity4225 ) raises clinical questions in terms of screening and prevention, particularly for an emergency @entity146 department. The purpose of this prospective study was to determine the risk factors of the recurrence of @entity146 during a one year follow-up in @entity4225 @entity1 consulting the emergency unit of the University Hospitals of Geneva (HUG) following a suicide attempt. METHODOLOGY: All subjects included in the study (age 18-65) had been diagnosed with @entity4225 according to DSM IV criteria. Furthermore, they all consulted the emergency @entity146 unit after a suicide attempt. The exclusion criteria were the presence of cognitive, @entity162 . Almost all @entity146 @entity1 from the Canton of Geneva (350 000 inhabitants) are directed to the HUG emergency department. After one year, 95 subjects were included in the study, while the total number of emergency @entity146 consultations was of about 10 000. During the emergency consultations, the clinicians checked the DSM IV criteria for @entity4225 and current @entity308 , following the usual guidelines, independently of the study. The clinicians were specifically trained to set up the diagnosis of @entity4225 by means of the International Personality Disorder Examination (IPDE). The gravity of @entity308 was assessed with the @entity308 ( @entity308 ). The recurrence of @entity146 was recorded for every @entity1 during one year. RESULTS: Among the 95 @entity1 included in the study, 34 @entity1 (36%) were re-admitted to the emergency unit for one or several @entity146 during the first year after inclusion. The recurrence of the @entity146 was significantly higher in @entity1 (OR=9.8), in @entity1 with past history of @entity146 (OR=8.9) and in @entity1 living alone (OR=2.5). Interestingly, the presence of a farewell letter seems to be a protective factor (OR=0.1) for @entity146 . Furthermore, low economic status appears to be associated with a higher recurrence risk, but the trend is not statistically significant. Recurrence and intensity ( @entity308 ) of the major @entity308 , @entity734 , and other disorders on @entity2270 I of DSM IV did not differ statistically in @entity1 with or without @entity146 recurrence. CONCLUSION: In this preliminary study, we tried to identify @entity1 at risk for @entity146 , relating to early secondary prevention, starting from the first assessment at the emergency unit.

title: [Predictive factors of suicidal behaviour recurrence in XXXX @entity1 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar or psychotic disorders']

entities_list: @entity4225 :: ('MESH:D001883', 'Disease') :: ['borderline personality disorder', 'BPD']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive disorders', 'Major Depressive Episode', 'Hamilton Depression Rating Scale', 'depressive episode', 'HDRS']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric', 'SB', 'suicidal behavior']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['drug addiction']

answer: @entity4225 :: (MESH:D001883,Disease) :: ['borderline personality disorder']


abstract: Recent meta-analyses documented the efficacy and safety of @entity13366 ( @entity13366 ) in @entity1 with @entity2023 ( @entity2023 ) @entity565 ( @entity565 ). Although @entity13366 appeared globally effective, the sub-analyses for single allergens provided uncertain results. This study is aimed to investigate the efficacy of @entity13366 with @entity6711 ( @entity6711 ) extracts in @entity2023 and @entity565 through an updated reassessment of randomized controlled trials. Electronic databases were searched up to March 31, 2008, for randomized DBPC trials, assessing the efficacy of @entity13366 in @entity2023 and @entity565 due to @entity6711 sensitization. Outcomes were symptom scores and rescue medications use. For @entity2023 , eight studies fulfilled the selection criteria. A significant @entity2023 ( @entity7126 -0.95; CI 95%-1.77 to -0.14 P = 0.02) was found in 194 @entity1 (adults and @entity1 ) receiving @entity13366 compared to 188 receiving placebo. For @entity565 , with nine studies, similar results were found for symptoms ( @entity7126 -0.95; CI 95%-1.74 to -0.15 P = 0.02) in 243 @entity1 (adults and @entity1 ) receiving @entity13366 compared to 209 receiving placebo. A reduction in rescue medication use was found for @entity2023 ( @entity7126 -1.88; CI 95%-3.65 to -0.12 P = 0.04) in 89 @entity1 , and @entity565 ( @entity7126 -1.48; CI 95%-2.70 to -0.26 P = 0.02) in 202 @entity1 . A relevant inter-study heterogeneity was detected. Promising evidence of efficacy for @entity13366 , using mite extract in @entity56 @entity1 suffering from @entity2023 and @entity565 , are herein shown. These findings suggest that more data are needed, derived from large-population-based high quality studies, and corroborated by objective outcomes, mainly for @entity565 .

title: The efficacy of XXXX for house dust mites respiratory allergy: results of a GA2LEN meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity2023 :: ('MESH:D006255', 'Disease') :: ['AR', 'reduction in symptoms of AR', 'allergic rhinitis']

entities_list: @entity565 :: ('MESH:D001249', 'Disease') :: ['AA', 'and asthma']

entities_list: @entity13366 :: ('MESH:D013362', 'Disease') :: ['SLIT', 'sublingual immunotherapy']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

entities_list: @entity6711 :: ('MESH:D008924', 'Disease') :: ['HDM', 'house dust mite']

answer: @entity13366 :: (MESH:D013362,Disease) :: ['sublingual immunotherapy']


abstract: INTRODUCTION: Many @entity1 at high risk of @entity174 are not following traditional guidelines and not being recommended for intervention. This study aimed to propose and evaluate a new set of intervention thresholds. METHODS: @entity1 were 213,375 @entity1 and @entity1 aged >= 50years living in New South Wales, Australia. Fracture Risk Assessment Paper Charts (Australia) was used to estimate the 10-year @entity174 risk. The standardized rates (to Australia population distribution 2007) for intervention were calculated for different thresholds: our proposed new thresholds (i.e. 10-year probability of hip @entity174 : >= 3%, 5% or 7% for 50-69, 70-79 and >= 80years respectively), thresholds by the National @entity170 Guideline Group (NOGG) approach, UK thresholds and US thresholds. RESULTS: The NOGG, UK and US thresholds did not work well in the Australian population. For example, the NOGG and UK thresholds respectively qualified only 1 in 12 (8.1%) and 1 in 9 (11.3%) Australian @entity1 aged >= 70years and the US thresholds qualified about 9 in 10 (90.6%) Australian @entity1 aged >= 70years. For @entity1 or @entity1 aged >= 70years, our proposed new thresholds gave more realistic treatment rates of 21.6% for @entity1 and 70.5% for @entity1 . Compared to the current Australian guidelines (i.e. T-score <=-2.5 and age>= 70years or a @entity174 ), our thresholds identified an additional 4.9% of @entity1 and 18.2% of @entity1 aged>= 70years for treatment. CONCLUSION: The proposed new thresholds could identify currently under-recognised high-risk individuals for treatment. It should be considered as a recommendation for @entity170 management in Australia.

title: Managing XXXX with FRAX   in Australia: Proposed new treatment thresholds from the 45_Up Study cohort.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Participants', 'people', 'men']

entities_list: @entity170 :: ('MESH:D010024', 'Disease') :: ['Osteoporosis', 'osteoporosis']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fragility fracture', 'fracture']

answer: @entity170 :: (MESH:D010024,Disease) :: ['osteoporosis']


abstract: @entity3003 ( @entity3003 , Bristol-Meyers, New York) is a second generation @entity902 analog. Preclinical and phase I clinical studies have indicated a different spectrum of @entity137 compared with the parent compound. In order to study the activity of @entity3003 against @entity135 , 31 @entity1 with recurrent or metastatic disease (30 squamous-cell and one @entity2347 ) were treated with doses of 60 to 80 mg/m2 administered daily by intravenous (IV) bolus injections for five days, repeated at every 4- to 5-week intervals. In most cases, treatment was administered on an outpatient basis. Eight @entity1 (26%; 95% confidence interval, 12% to 45%) had complete (CR) or partial responses (PR) with a median duration of 4.5 months. Moderate @entity236 was the main @entity137 . Mild @entity1209 was unusual and no neuro- or nephrotoxicity were seen. These preliminary data suggest that @entity3003 has activity against advanced squamous-cell @entity135 comparable with the results reported with @entity900 alone in similar @entity1 populations. The potential advantages over the parent compound relate to the absence of nephrotoxic effects and mild @entity344 which allows for outpatient treatment. Because @entity3003 @entity137 is directly dependent on its mechanism of @entity8 , particular attention should be given for its use in @entity1 with @entity8 or when combined with nephrotoxic agents. Similarly, because the dose limiting @entity137 with this agent is primarily hematologic, its use in combination with other myelotoxic agents should be carefully undertaken. Further studies are indicated in order to define the spectrum of activity of the new generation @entity902 analogs in various @entity5 in @entity1 .

title: @entity3003 ( XXXX ): an active @entity902 analog for the treatment of squamous-cell @entity135 .

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'patients', 'patient']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['cancer of the head and neck', 'carcinoma of the head and neck']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['impaired renal function', 'renal excretion']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'CBDCA', 'carboplatin']

entities_list: @entity2347 :: ('MESH:D003528', 'Disease') :: ['adenoid cystic carcinoma']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal toxicity']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow suppression']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['nausea and vomiting']

answer: @entity3003 :: (MESH:D016190,Chemical) :: ['NSC-241-240']


abstract: MicroRNAs (miRNAs) are key regulators in cell processes. Emerging evidence has suggested that there is a direct association between miRNAs and @entity5 . However, the exact regulatory mechanisms of miRNAs in tumorigenesis are poorly understood. In the present study, we showed that @entity3373 is able to significantly reduce mRNA and protein expression levels of A disintegrin and metalloproteinase  17 ( @entity3375 ) in @entity96 cells (SMMC-7721, BEL-7402 and @entity5959 ). Dual luciferase reporter assays confirmed that @entity3375 is a direct target of @entity3373 . Notably, we found that @entity3373 inhibits cell proliferation and growth activity in SMMC-7721 cells. These results demonstrated that it may be exert the function of @entity5 suppression in a particular link of @entity5 cell growth. Further studies revealed that the silencing of @entity3375 decreased the proliferation and growth activity of SMMC-7721 cells. Moreover, it reduced the expression of @entity1495 . In conclusion, @entity3373 inhibits @entity96 cell proliferation by directly targeting @entity3375 . Thus, it may become a promising biological target in the treatment strategy of @entity157 .

title: MicroRNA-145 inhibits cell proliferation by directly targeting XXXX in @entity157 .

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma']

answer: @entity3375 :: (6868,Gene) :: ['ADAM17']


abstract: A review of 197 @entity1 with bone @entity3 from @entity0 was undertaken to assess the effect of adjuvant parasternal irradiation on the distribution of those @entity3 . A total of 128 @entity1 (Group I) received radiation. The control group consisted of 69 @entity1 (Group II) who did not receive adjuvant radiation. The dose absorbed by the mid-thoracic vertebrae (T3 to T8) varied from 10 Gy in 3 weeks to 20 Gy in 4 weeks. The distribution of bone @entity3 was analyzed at the initial development in the 197 @entity1 . Repeat assessments (X ray/scans) were available for analysis in 132 @entity1 . @entity1 in Group I had less @entity3 from T3 to T8: 37/128 (29%), vs 30/69 (43.5%) for @entity1 in Group II: (chi 2 = 3.62; p less than 0.10). For the 132 @entity1 with serial assessments, the difference at last evaluation was more significant: 45/86 (52%) in Group I, vs 36/46 (78%) in Group II: (chi 2 = 7.44; p less than 0.01). The data shows that @entity1 receiving low-dose exit beam irradiation from the parasternal field have fewer mid-thoracic bone @entity3 . Potential implications are discussed.

title: Does parasternal irradiation reduce thoracic vertebral XXXX in @entity0 ?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastases']


abstract: RATIONALE: @entity1030 ( @entity1030 ) is defined by the presence of airflow limitation on spirometry, yet @entity1030 subjects can have marked differences in CT imaging. These differences may be driven by genetic factors. We hypothesized that a genome-wide association study of quantitative imaging would identify loci not previously identified in analyses of @entity1030 or spirometry. In addition, we sought to determine whether previously described genome-wide significant @entity1030 and spirometric loci were associated with @entity2415 or airway phenotypes. OBJECTIVE: To identify genetic determinants of quantitative imaging phenotypes. METHODS: We performed a genome-wide association study on two quantitative @entity2415 and two quantitative airway imaging phenotypes in the COPDGene (non-Hispanic white and African-American), ECLIPSE, NETT, and GenKOLS studies; and on % gas trapping in COPDGene. We also examined specific loci reported as genome-wide significant for spirometric phenotypes related to airflow limitation or @entity1030 . RESULTS: The total sample size across all cohorts was 12,031, of which 9,338 were from COPDGene. We identified five loci associated with @entity2415 -related phenotypes, one with airway-related phenotypes, and two with gas trapping. These loci included previously reported associations, including the @entity21156 , 15q25, and @entity4283 loci, as well as novel associations near @entity21157 and @entity21158 . All previously reported @entity1030 and a significant number of spirometric GWAS loci were at least nominally (P < 0.05) associated with either @entity2415 or airway phenotypes. CONCLUSIONS: Genome-wide analysis may identify novel risk factors for quantitative imaging characteristics in @entity1030 , and also identify imaging features associated with previously identified lung function loci.   .

title: A Genome-wide Association Study of XXXX and Airway Quantitative Imaging Phenotypes.

entities_list: @entity2415 :: ('MESH:D004646', 'Disease') :: ['emphysema']

entities_list: @entity1030 :: ('MESH:D029424', 'Disease') :: ['Chronic obstructive pulmonary disease', 'COPD']

answer: @entity2415 :: (MESH:D004646,Disease) :: ['Emphysema']


abstract: @entity320 of the head and neck can metastasize to lymph nodes within the parotid gland. Selective lymphadenectomy is the modern method of staging regional lymph node basins in clinically localized @entity320 . This procedure involves intraoperative lymphatic mapping and directed, selective removal of the first draining nodes or sentinel lymph nodes (SLNs). Historically, the assessment of parotid lymph nodes would involve a superficial parotidectomy with @entity2103 . Since 1993, 28 @entity1 with localized @entity320 of the head and neck have demonstrated lymphatic drainage to parotid lymph nodes on preoperative lymphoscintigraphy. The overall success rate of parotid selective lymphadenectomy is 86% (24 of 28 @entity1 ). Of the 28 @entity1 , there were 6 early @entity1 in whom blue dye alone was utilized intraoperatively, and the success rate is 50% (3 of 6 @entity1 ). When blue dye and radiocolloid mapping techniques are combined, the parotid selective lymphadenectomy is successful in 95% of @entity1 (21 of 22 @entity1 ). Four of the 24 @entity1 (17%) had @entity3 to the SLNs and underwent therapeutic superficial parotidectomy and/or modified radical neck dissection. After completion of the therapeutic superficial parotidectomy, 1 of the 4 @entity1 was found to have an additional parotid (nonsentinel) node with @entity320 @entity3 . None of the @entity1 incurred @entity2123 by parotid selective lymphadenectomy. To date, 2 of 28 @entity1 (7%) have had regional recurrence to the parotid gland. Failure of the @entity4298 technique may occur when blue dye alone is used, when human serum albumin (not @entity599 colloid) is the radiocolloid, when prior wide excision and skin graft is present before lymphatic mapping, and when all SLNs are not retrieved. We conclude that parotid selective lymphadenectomy is a safe and reliable alternative to superficial parotidectomy for staging clinically localized @entity320 of the head and neck.

title: Parotid selective lymphadenectomy in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2123 :: ('MESH:D020220', 'Disease') :: ['injury to the facial nerve']

entities_list: @entity2103 :: ('MESH:D005155', 'Disease') :: ['facial nerve dissection']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'Malignant melanoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['malignant melanoma']


abstract: BACKGROUND: @entity311 is a major public health problem in Ghana. The current strategy of the National @entity311 Control Programme is based on effective case management and the use of insecticide treated bed nets among vulnerable groups such as @entity1 under-five years of age and pregnant @entity1 . Resistance to @entity312 by @entity313 s.l. and @entity314 has been reported in several African countries including neighbouring Burkina Faso. METHODS: Indoor resting Anopheles mosquitoes were collected. Blood-fed and gravid females were allowed to oviposit, eggs hatched and larvae reared to 1-3 days old adults and tested against @entity315 0.75%, @entity316 0.05%, @entity317 0.15%, lambdacyhalothrin 0.1% and @entity318 4%, based on WHO methodology. PCR analyses were carried out on a sub-sample of 192 of the An. gambiae for sibling species complex determination. Resistance to @entity312 and @entity318 was determined by genotyping the knock-down resistance @entity319 gene mutations in the study area. RESULTS: A total of 9,749 1-3 days-old F1 female Anopheles mosquitoes were exposed to the insecticides. Among the @entity312 , @entity315 , 0.75% had the least knockdown effect, whilst @entity317 0.15%, had the highest knock-down effect. Overall, no difference in susceptibility between An. gambiae 93.3% (95% CI: 92.5-94.1) and An. funestus 94.5% (95% CI: 93.7-95.3) was observed when exposed to the @entity312 . Similarly, there was no difference in susceptibility between the two vector species (An. gambiae = 79.1% (95% CI: 76.6-81.8) and An. funestus = 83.5% (95% CI: 80.2-86.4) when exposed to @entity318 . Overall susceptibility to the insecticides was between 80% and 98%, suggesting that there is some level of resistance, except for @entity317 0.15%. The @entity319 PCR assay however, did not reveal any @entity319 mutations. The analysis also revealed only the molecular M (Mopti) form. CONCLUSION: The findings in this study show that An. gambiae and An. funestus, the main @entity311 vector mosquitoes in the Kassena-Nankana district are susceptible to the insecticides being used in the treatment of bed nets in the @entity311 control programme. There is however, the need for continuous monitoring of the @entity312 as the efficacy is not very high.

title: Insecticide resistance profiles for XXXX vectors in the Kassena-Nankana district of Ghana.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'children']

entities_list: @entity317 :: ('MESH:C052570', 'Chemical') :: ['cyfluthrin']

entities_list: @entity314 :: ('62324', 'Species') :: ['Anopheles funestus']

entities_list: @entity312 :: ('MESH:D011722', 'Chemical') :: ['pyrethroids']

entities_list: @entity316 :: ('MESH:C017180', 'Chemical') :: ['deltamethrin']

entities_list: @entity315 :: ('MESH:D026023', 'Chemical') :: ['permethrin']

entities_list: @entity311 :: ('MESH:D008288', 'Disease') :: ['Malaria', 'malaria']

entities_list: @entity313 :: ('7165', 'Species') :: ['Anopheles gambiae']

answer: @entity311 :: (MESH:D008288,Disease) :: ['malaria']


abstract: OBJECTIVE: To determine whether @entity282 and @entity390 after laparoscopic sterilization can be reduced with a combination of @entity1341 , @entity1769 , @entity5591 , @entity6058 , and gastric suctioning. METHODS: @entity1 undergoing outpatient laparoscopic sterilization were randomized to protocol management or nontreatment groups. Each @entity1 received standard general endotracheal anesthesia. Protocol subjects received intramuscular @entity6058 60 mg and @entity5591 0.25 mg, intravenous @entity1769 10 mg, and gastric suctioning; @entity1341 (2.5 mg/mL) with @entity1425 (5 micrograms/mL) was injected at trocar sites and dripped onto the fallopian tubes. The nontreatment group served as controls. Visual analogue scales were used to evaluate @entity158 and @entity390 (measured in millimeters). Demographic characteristics, postoperative requirements for analgesics and antiemetics, time to discharge, and unscheduled admission were also evaluated. RESULTS: During a 7-month period, 71 @entity1 were enrolled. Protocol subjects (N = 35) reported @entity158 severity of 27.9 +/- 19.1 mm (mean +/- standard deviation), whereas controls (N = 36) reported 59.3 +/- 23.3 mm (P < .001). Fourteen protocol @entity1 requested additional @entity158 medication, compared with 29 controls (P < .001). Protocol @entity1 indicated a @entity390 severity of 9.9 +/- 18.7 mm, whereas the controls reported 38.8 +/- 35.5 mm (P < .001). Only one protocol @entity1 required @entity390 medication, compared with nine controls (P < .02). Severity of @entity158 correlated with severity of @entity390 (r = 0.38166, P < .001). Protocol @entity1 were discharged from the outpatient surgery unit in 148.6 +/- 45.0 minutes, compared with 176.4 +/- 58.5 minutes for controls (P < .03). CONCLUSION: This regimen reduced the severity of @entity158 and @entity390 after outpatient laparoscopic sterilization. The need for additional analgesics and antiemetics was also reduced. Protocol @entity1 were discharged earlier than controls. These benefits seem to accrue without significant risk. We believe that this regimen may also be useful in other ambulatory laparoscopic procedures.

title: Reduction of @entity158 and @entity390 after laparoscopic sterilization with @entity1341 , @entity1769 , XXXX , @entity6058 , and gastric suctioning.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women', 'patient']

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['epinephrine']

entities_list: @entity6058 :: ('MESH:D020910', 'Chemical') :: ['ketorolac']

entities_list: @entity1341 :: ('MESH:D002045', 'Chemical') :: ['bupivacaine']

entities_list: @entity1769 :: ('MESH:D008787', 'Chemical') :: ['metoclopramide']

entities_list: @entity5591 :: ('MESH:D012601', 'Chemical') :: ['scopolamine']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain']

answer: @entity5591 :: (MESH:D012601,Chemical) :: ['scopolamine']


abstract: BACKGROUND: @entity134 therapy profoundly inhibits lymphocyte migration into @entity1600 ( @entity1600 ), thereby disrupting lymphocyte recirculation. This study was undertaken in @entity1 subjects to examine two nonmutually exclusive hypotheses proposed to explain this @entity134 effect: (1) @entity230 decrease the capacity of @entity1600 high endothelial venules ( @entity4973 ) to support lymphocyte adherence; and/or (2) @entity230 alter the expression of lymphocyte adhesion molecules specific for entry into LNs. METHODS: @entity1 LNs were obtained from cadaveric organ donors before and after @entity1667 infusion and examined for their capacity to support lymphocyte adherence using an in vitro lymphocyte- @entity4973 adherence assay. Additionally, six healthy volunteers underwent infusions of saline (placebo) and @entity1667 (3 mg/kg in saline), and peripheral blood lymphocytes were isolated before, immediately after, and at 1, 2, 4, 8, 24, and 48 hours following infusions. At each timepoint, flow cytometric analysis of lymphocyte @entity1196 , @entity1759 , and @entity1453 expression was assessed. Short-term tissue culture studies were also performed to examine the direct effects of @entity230 on the expression of these lymphocyte proteins. RESULTS: LNs obtained from organ donors before and after @entity134 infusion displayed no differences in the capacity of @entity4973 to support lymphocyte adherence. In controlled @entity134 infusion studies, @entity2905 was observed within 1 hour and persisted for 8 hours. Cells isolated during the period of @entity2905 did not adhere to @entity1600 @entity4973 , and there was a marked decrease in both the percentage and mean fluorescence intensity level of @entity1196 + lymphocytes; minor changes were observed in the percentage of @entity1759 + and @entity1453 + cells, while the mean fluorescence intensity level decreased for @entity1759 + cells and increased for @entity1453 + cells. All such changes in adhesion protein levels among circulating cells reversed with the resolution of @entity2905 . However, in tissue culture experiments, @entity230 did not alter the expression of lymphocyte adhesion proteins. CONCLUSIONS: The decreased migration of lymphocytes to @entity1600 following @entity134 administration is not due to changes in the capacity of @entity4973 to bind lymphocytes, but results from decreases in the level of @entity1196 expressed among circulating cells. Culture studies suggest that @entity230 do not directly alter lymphocyte adhesion protein expression. The possibility that these agents act indirectly by stimulating the release and/or promoting the activity of relevant biologic mediators affecting lymphocyte adhesion protein expression needs further exploration.

title: The effects of corticosteroids on lymphocyte recirculation in @entity1 : analysis of the mechanism of impaired lymphocyte migration to lymph node following XXXX administration.

entities_list: @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone']

entities_list: @entity2905 :: ('MESH:D008231', 'Disease') :: ['lymphopenia']

entities_list: @entity1600 :: ('MESH:D014388', 'Disease') :: ['LN', 'lymph nodes']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['Steroid', 'steroid']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

answer: @entity1667 :: (MESH:D008775,Chemical) :: ['methylprednisolone']


abstract: BACKGROUND: Covered biliary metal stents have been developed to prevent @entity5 ingrowth. Previous comparative studies are limited and often include few @entity1 . OBJECTIVE: To compare differences in stent patency, @entity1 survival, and complication rates between covered and uncovered @entity5648 stents in @entity1 with @entity5 . DESIGN: Randomized, multicenter trial conducted between January 2006 and October 2008. SETTING: Ten sites serving a total catchment area of approximately 2.8 million inhabitants. @entity1 : A total of 400 @entity1 with unresectable distal @entity5 . INTERVENTIONS: ERCP with insertion of covered or uncovered metal stent. Follow-up conducted monthly for symptoms indicating stent obstruction. MAIN OUTCOME MEASUREMENTS: Time to stent failure, survival time, and complication rate. RESULTS: The @entity1 survival times were 116 days (interquartile range 242 days) and 174 days (interquartile range 284 days) in the covered and uncovered stent groups, respectively (P = .320). The first quartile stent patency time was 154 days in the covered stent group and 199 days in the uncovered stent group (P = .326). There was no difference in the incidence of @entity788 or @entity2679 between the 2 groups. Stent migration occurred in 6 @entity1 (3%) in the covered group and in no @entity1 in the uncovered group (P = .030). LIMITATIONS: Randomization was not blinded. CONCLUSIONS: There were no significant differences in stent patency time, @entity1 survival time, or complication rates between covered and uncovered @entity5648 metal stents in the palliative treatment of @entity5 . However, covered stents migrated significantly more often compared with uncovered stents, and @entity5 ingrowth was more frequent in uncovered stents.

title: Covered versus uncovered self-expandable XXXX stents in the palliative treatment of @entity5 : results from a randomized, multicenter study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignant distal biliary obstruction', 'malignant biliary obstruction']

entities_list: @entity2679 :: ('MESH:D002764', 'Disease') :: ['cholecystitis']

answer: @entity5648 :: (MESH:C013616,Chemical) :: ['nitinol']


abstract: INTRODUCTION: Few multiple behavior change interventions have addressed @entity286 use in conjunction with fruit and vegetable consumption, particularly among high-risk blue-collar workers. Tools for Health, a @entity5 prevention intervention for construction laborers, was effective in achieving behavior change for smoking cessation and fruit and vegetable consumption separately. This study examines whether addressing smoking and fruit and vegetable consumption was successful in achieving positive change for both behaviors. We also explored possible explanations for the relationship between behavior changes in these 2 behavioral domains. METHODS: We retrospectively analyzed data from a randomized controlled trial testing a smoking cessation and fruit and vegetable consumption intervention for construction workers. We used survey data from 300 intervention @entity1 to answer our primary research question: Did @entity1 who reported being smokers at baseline successfully quit smoking and increase their fruit and vegetable consumption by the end of the intervention? We used qualitative data from 16 small group discussions to help interpret these results. RESULTS: Tools for Health @entity1 achieved substantial levels of smoking cessation and increased their fruit and vegetable consumption, concurrently, during the course of the intervention. CONCLUSION: This study provides evidence that pairing smoking cessation with increasing fruit and vegetable consumption can be successful in a multiple behavior change intervention designed for high-risk blue-collar workers. Further, our findings provide potential directions for examining why this pairing might be complementary.

title: Multiple health behavior changes in a XXXX prevention intervention for construction workers, 2001-2003.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']